These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18620461)

  • 1. Demand forecasting for preventive AIDS vaccines: economic and policy dimensions.
    Hecht R; Gandhi G
    Pharmacoeconomics; 2008; 26(8):679-97. PubMed ID: 18620461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries.
    Harmon TM; Fisher KA; McGlynn MG; Stover J; Warren MJ; Teng Y; Näveke A
    PLoS One; 2016; 11(1):e0146387. PubMed ID: 26731116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
    Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
    Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012.
    Moodley N; Gray G; Bertram M
    BMC Public Health; 2016 Apr; 16():330. PubMed ID: 27079900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study).
    Esparza J; Chang ML; Widdus R; Madrid Y; Walker N; Ghys PD
    Vaccine; 2003 May; 21(17-18):2032-41. PubMed ID: 12706693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global immunization against AIDS: economic considerations.
    Petricciani JC
    Vaccine; 1993; 11(8):873-7. PubMed ID: 8356848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast.
    Cowley P
    Health Policy; 1993 May; 24(2):145-53. PubMed ID: 10128800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.
    Mogasale V; Ramani E; Park IY; Lee JS
    Hum Vaccin Immunother; 2017 Sep; 13(9):2017-2024. PubMed ID: 28604164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries.
    Debellut F; Hendrix N; Pitzer VE; Neuzil KM; Constenla D; Bar-Zeev N; Marfin A; Pecenka C
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S154-S160. PubMed ID: 30845321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study.
    Haakenstad A; Moses MW; Tao T; Tsakalos G; Zlavog B; Kates J; Wexler A; Murray CJL; Dieleman JL
    Lancet HIV; 2019 Jun; 6(6):e382-e395. PubMed ID: 31036482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.
    Andersson KM; Paltiel AD; Owens DK
    Vaccine; 2011 Aug; 29(36):6107-12. PubMed ID: 21736912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strengthening global vaccine access for adolescents and adults.
    Nanni A; Meredith S; Gati S; Holm K; Harmon T; Ginsberg A
    Vaccine; 2017 Dec; 35(49 Pt B):6823-6827. PubMed ID: 29122384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.
    AIDS; 2001 May; 15(7):W27-44. PubMed ID: 11399975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.